Related Experiment Video

Updated: Jun 10, 2025

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.0K

MAPK pathway and NIS in B-CPAP human papillary thyroid carcinoma cells treated with resveratrol

Gokcen Unal Kocabas1, Asli Kisim Blatti2, Afig Berdeli3

  • 1Department of Endocrinology and Metabolism, Ege University School of Medicine, Izmir, Turkey.

Pathology, Research and Practice
|October 15, 2024
PubMed
Abstract

Insights

Resveratrol inhibits thyroid cancer cell proliferation by reducing BRAF and ERK expression and increasing NIS expression. Further research is needed to explore its therapeutic potential for papillary thyroid cancer.

Area of Science:

  • Molecular Biology
  • Oncology
  • Pharmacology

Background:

  • Resveratrol, a natural phytoalexin, exhibits known anti-tumor properties.
  • Thyroid cancer cells are a target for resveratrol's potential therapeutic effects.

Purpose of the Study:

  • To investigate the impact of resveratrol on BRAF, ERK, and NIS mRNA and protein expression.
  • To assess resveratrol's effects on B-CPAP human thyroid papillary cancer cell line.

Main Methods:

  • B-CPAP cells were treated with varying concentrations of resveratrol (10-100 μM) over 24-72 hours.
  • Cell viability was measured using XTT assay.
  • BRAF, ERK, and NIS mRNA and protein levels were analyzed via rt-PCR and Western Blot.

Main Results:

  • Resveratrol demonstrated dose- and time-dependent inhibition of cell proliferation.
  • Significant reductions in BRAF and ERK mRNA and protein levels were observed.
  • A notable increase in NIS mRNA and protein expression was documented.

Conclusions:

  • Resveratrol effectively inhibits papillary thyroid cancer cell proliferation.
  • The compound downregulates poor prognostic markers BRAF and ERK while upregulating NIS, indicating a potential redifferentiating effect.
  • Resveratrol warrants further investigation as a novel therapeutic agent for papillary thyroid cancer.
Keywords:
BRAFERKNISResveratrolThyroid papillary cancer

More Related Videos

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice00:07

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.2K
Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes15:43

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes

Published on: January 7, 2013

18.1K

Related Concept Videos

NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
7.3K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.2K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.1K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
143